Mace Rothenberg bought $74k of TNGX
director at Tango Therapeutics, Inc.. 20,000 shares at an average of $3.70, traded Nov 14, 2024, filed Nov 18, 2024.
Score components
- +15RoleDirector
- +8Trade size$74k at market
- +10Relative to holdingsHoldings up 178%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -22.5%, 3m -31.4%, 6m -36.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-128163, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 14, 2024 | POpen-market purchase Common Stock | +10,000 | $3.62 | $36k | 21,250 | Nov 18, 2024 |
| Nov 18, 2024 | POpen-market purchase Common Stock | +10,000 | $3.78 | $38k | 31,250 | Nov 18, 2024 |
Related signals
Other insiders at Tango Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 18Weak | Tango Therapeutics, Inc. | Adam Crystal President, R&D | $661k 27,000 shares | -19% | |
| 20Weak | Tango Therapeutics, Inc. | Jessica Newcomb Principal Accounting Officer | $199k 8,200 shares | -12% | |
| 9Weak | Tango Therapeutics, Inc. | Adam Crystal President, R&D | $604k 27,000 shares | -19% | |
| 30Weak | Tango Therapeutics, Inc. | Douglas Barry General Counsel | $16k 5,330 shares | -7% | |
| 42Moderate | Tango Therapeutics, Inc. | Daniella Beckman Chief Financial Officer | $25k 8,232 shares | -5% | |
| 36Weak | Tango Therapeutics, Inc. | Adam Crystal See Remarks | $44k 14,283 shares | -8% | |
| 50Moderate | Tango Therapeutics, Inc. | EcoR1 Capital, LLC owner | $8.4M 2,700,000 shares | -20% | |
| 51Moderate | Tango Therapeutics, Inc. | Boxer Capital Management, LLC other | $9.7M 3,080,000 shares | -46% | |
| 41Moderate | Tango Therapeutics, Inc. | Boxer Capital Management, LLC other | $4.3M 633,000 shares | -9% | |
| 38Weak | TNGXsell Tango Therapeutics, Inc. | Boxer Capital Management, LLC other | $6.1M 875,000 shares | -11% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.